Rock Springs Capital COLL Position
ExitedRock Springs Capital exited their position in COLLEGIUM PHARMACEUTICAL, INC (COLL) in Q2 2024, after holding the stock for 6 quarters.
The position was first reported in Q1 2023 and has been tracked across 6 quarterly 13F filings.
2 other tracked funds also hold COLL.
Short interest stands at 16.1% of float with 9.9 days to cover, indicating significant bearish positioning against the stock.
About COLLEGIUM PHARMACEUTICAL, INC
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Full company profile →Short Interest
16.1%
9.9 days to cover
Rock Springs Capital COLL Position History
Frequently Asked Questions
Does Rock Springs Capital own COLL?
No. Rock Springs Capital exited their position in COLLEGIUM PHARMACEUTICAL, INC (COLL) in Q2 2024. They previously held the stock for 6 quarters.
How many hedge funds own COLL?
2 specialist biotech hedge funds currently hold COLL, including Eventide Asset Management, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy COLL?
Rock Springs Capital's position in COLL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's COLL position increasing or decreasing?
Rock Springs Capital completely exited their COLL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
COLLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →